Navigation Links
Interleukin Genetics Grants LABEC Pharma a License for Sales and Distribution of Its Heart Health Genetic Test
Date:4/6/2009

- LABEC Pharma to Introduce Test Product in Spain and Portugal

- Companies plan to seek CE Mark

WALTHAM, Mass. and MADRID, Spain, April 6 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) and LABEC Pharma, S.L. announced today that the companies have entered a licensing agreement to permit LABEC Pharma to market and sell Interleukin Genetics' Heart Health genetic test throughout Spain and Portugal. This molecular diagnostic tool helps to identify individuals at elevated risk for early heart attack. As part of the agreement, the test will be marketed by LABEC Pharma and the tests will be processed at Interleukin Genetics' CLIA-certified laboratory in Waltham, MA. Interleukin Genetics will receive royalties and commercial milestone payments. The Interleukin Genetics' Heart Health test is currently marketed within the United States under the brand name Gensona(R).

"We are excited about this partnership with LABEC Pharma, which will allow for broader and international distribution of this important genetic test product," said Lewis H. Bender, CEO, Interleukin Genetics, Inc. "Our Heart Health genetic test can give a better understanding of a person's overall risk for heart attack, so that individuals and their physicians can begin to take the steps necessary for lowering risk to improve health outcomes."

"Early intervention is a critical step in helping people stay healthy. We are pleased to begin offering the Interleukin Genetics' Heart Health genetic test, which we believe fits well with our existing sales efforts in diagnostic products for disease management and prevention. Being able to offer this test in Spain and Portugal is great news for patients in these two countries," said Javier de Echevarria, CEO, LABEC Pharma.

In recent ye
'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Interleukin Genetics Receives NYSE Amex Staff Determination, Requests Oral Hearing Before the Listing Qualifications Panel
2. Interleukin Genetics Announces Conference Call to Discuss Fourth Quarter 2008 Results
3. Interleukin Genetics to Present at G-2 Reports Molecular Diagnostic Conference
4. Interleukin Genetics Submits Plan to Regain Compliance with Continued Listing Standards
5. Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss
6. Novel bioreactor enhances interleukin-12 production in genetically-modified tobacco plants
7. Interleukin Genetics Announces Conference Call and Webcast to Discuss Third Quarter 2008 Business Results
8. Interleukin Genetics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
9. Interleukin-12 indicates survival prospects for melanoma patients
10. LaVoie Group Adds Interleukin Genetics to its Life Science Agency Roster
11. Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... , PHILADELPHIA, June 19 Kensey Nash Corporation (Nasdaq: ... and President, received the Ernst & Young Entrepreneur Of The ... in the greater Philadelphia region. According to Ernst & ... and leading dynamic, growing businesses. Joe Kaufmann was selected ...
... cases of E. coli infection in 28 states ... are warning consumers not to eat any Nestlé Toll House ... E. coli contamination. , In response to the Food ... was voluntarily recalling its Toll House refrigerated cookie dough items. ...
... ... which provides an invaluable service to many patients who need blood products. , ... Washington (Vocus) June 19, 2009 -- Children,s ... which provides an invaluable service to many patients who need blood products. Children,s National is ...
... levels in patients , FRIDAY, June 19 (HealthDay News) ... may explain brain gray matter reductions experienced by patients ... found an association between fibromyalgia and reductions in gray ... , In this new study, Dr. Patrick B. Wood, ...
... ARDEE, Ireland, June 19 Warner Chilcott Limited (Nasdaq: ... Wachovia,s 19th Annual Mid-Year Equity Conference on Wednesday, June 24, ... will be Rochelle Fuhrmann, Senior Director, Investor Relations. , ... interested parties at www.wcrx.com under the Investor Relations ...
... ... Control Spread of Infectious Diseases , ... Fargo, ND (PRWEB) June 19, 2009 - Last week, the World Health Organization declared ... state health officials in the U.S. are urging healthcare providers to take precautions to limit ...
Cached Medicine News:Health News:Kensey Nash Corporation's CEO & President, Joe Kaufmann Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Winner in Greater Philadelphia Region 2Health News:Kensey Nash Corporation's CEO & President, Joe Kaufmann Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Winner in Greater Philadelphia Region 3Health News:Nestlé Recalls Cookie Dough Products 2Health News:Children's National Medical Center Dedicates New Blood Donor Center 2Health News:Children's National Medical Center Dedicates New Blood Donor Center 3Health News:Real-Time Locating Technology Helps Contain Pandemic Outbreaks 2Health News:Real-Time Locating Technology Helps Contain Pandemic Outbreaks 3Health News:Real-Time Locating Technology Helps Contain Pandemic Outbreaks 4
(Date:12/24/2014)... Dec. 24, 2014  Actavis plc (NYSE: ... has received a complete response letter from the ... New Drug Application (NDA) for the fixed-dose combination ... of hypertension.   Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... in the receipt of a complete response letter, ...
(Date:12/24/2014)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... preliminary financial results for the first quarter of ... Ended September 30, 2014 Financial Highlights: , ... in 1Q14 with gross margins improved to 52% ...
(Date:12/24/2014)... N.J. , Dec. 24, 2014 ... a late-stage biopharmaceutical company developing products that address ... oncology and biodefense, announced today that on December ... public offering. The Company raised approximately ... and intends to use the net proceeds from ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... Avaulta™ BioSynthetic Mesh ... mesh coated in the ... absorbable, hydrophilic film of ... segments of the Avaulta™ ...
The Repliform Tissue Regeneration Matrix is an acellular human dermal allograft that when surgically implanted is intended to function as a template, facilitating the body's fibroblasts to regenerate...
... Pelvicol® Acellular Collagen Matrix delivers the ... exceptional strength, versatility, and durability in ... the effectiveness of site-specific defect repair ... sterile, biocompatible, crosslinked porcine dermal collagen ...
... The QIAamp Viral RNA ... viral nucleic acids from cell-free ... nucleic acids that can be ... but are not limited to, ...
Medicine Products: